INTRODUCTION Computational fluid dynamics (CFD) has recently seen increased use in the design of pharmaceutical inhalers. The use of CFD in the design of inhalers is made difficult by the complex nature of aerosol generation. At present, CFD has provided valuable insight into certain aspects of inhaler performance, though limitations in computational power have prevented the full implementation...

BACKGROUND AND PURPOSE CFD has been proved valuable for simulating blood flow in intracranial aneurysms, which may add to better rupture risk assessment. However, CFD has drawbacks such as the sensitivity to assumptions needed for the model, which may hinder its clinical implementation. 3D PC-MR imaging is a technique that enables measurements of blood flow. The purpose of this study was to com...

Abstract: The latest release of Abaqus version 6.10 includes Abaqus/CFD. The inclusion of this software makes it possible for users to perform a fluid analysis in a more user-friendly manner. Independent single software solely for CFD is currently available from many developers, and many attempts have been made to link software of CFD to structural analysis system using some specific procedures...

Introduction: Knowledge of blood flow patterns in the human body is a critical component in cardiovascular disease diagnosis. In-vivo blood flow is typically assessed either by 3D phase-contrast MRI [1], or by Computational Fluid Dynamics (CFD) calculations [2]. MRI measurements are direct, but offer limited spatio-temporal resolution. Conventional CFD calculations offer "infinite" spatial reso...

AIM The aim of the current study is to assess the mortality prediction accuracy of circulating cell-free DNA (CFD) level at admission measured by a new simplified method. MATERIALS AND METHODS CFD levels were measured by a direct fluorescence assay in severe sepsis patients on intensive care unit (ICU) admission. In-hospital and/or twenty eight day all-cause mortality was the primary outcome....

This study aims to assess cell-free DNA (CFD) by a fluorescence assay as a biomarker for early prediction of a pathologic complete response (pCR) and relapse in patients with triple-negative breast cancer (TNBC) undergoing neoadjuvant chemotherapy. Patients with clinical stage II or III TNBC scheduled for neoadjuvant chemotherapy were prospectively enrolled. All patients underwent four cycles o...